NewAmsterdam Pharma Company N.V. - Ordinary Shares — Balance Sheet (NASDAQ:NAMS) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets —347.1 M864.62 M769.28 M Total liabilities —58.7 M107.12 M85.85 M Total equity —288.39 M757.5 M683.43 M Total liabilities & shareholders' equities —347.1 M864.62 M769.28 M Total debt ———— Net debt ————

News

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - Slideshow (NASDAQ:NAMS) 2026-05-11

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates

AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights

Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight

Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing

NewAmsterdam Pharma earnings missed by $0.23, revenue fell short of estimates

NewAmsterdam expects EMA decision on cholesterol drug in second half 2026

NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners

Piper Sandler highlights commercial biotech names to own in 2026

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript